Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Bozkaya, Yakup; Erdem, Gökmen Umut; Özdemir, Nuriye; Demi̇rci, Nebi̇ Serkan; Hocazade, Cemil; Yazıcı, Ozan; Zengi̇n, Nurullah

doi:10.1080/03007995.2016.1239192

Cited by 14 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stage IV gastric signet ring cell carcinoma has long been considered to have worse survival rates compared with other types of adenocarcinoma . Previous studies reported that gastric SRCC had high proportion of patients with poorly differentiated grade, younger age and female gender, which was consistent with the clinicopathological characteristics identified in our study. As to metastasis, the mechanism behind the formation of signet ring cell carcinoma may contribute to its unique features.…”

Section: Discussionsupporting

confidence: 91%

“…Adenocarcinomas represent the majority of gastric cancers, while signet ring cell carcinoma (SRCC) is a poorly differentiated subtype of gastric carcinoma with unique clinical characteristics and poor survival rates . Previous studies indicated that gastric SRCC has different risk factors compared to non‐SRCC gastric cancer (NOS) types, including older age, female gender, smoking, obesity and American Joint Committee on Cancer (AJCC) IV stage . Pathologically, gastric SRCC consists of scattered malignant cells containing abundant intracytoplasmic mucin, and is associated with rapid growth and diffuse infiltration of surrounding tissues .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study

et al. 2019

View full text Add to dashboard Cite

Background Stage IV gastric signet ring cell carcinoma (SRCC) is a type of malignant gastric cancer (GC) with poorer survival compared to metastatic non‐SRCC gastric cancer (NOS). However, chemotherapy alone was unable to maintain long‐term survival. This study aimed to evaluate survival benefit of palliative gastrectomy plus chemotherapy (PG+C) for metastatic gastric SRCC. Methods We obtained data on gastric cancer patients between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Statistical methods included χ2 tests, Kaplan‐Meier curves, COX models, propensity score matching (PSM) and subgroup analysis. Results Among 27 240 gastric cancer patients included, 4638 (17.03%) were SRCC patients. The proportion of patients with younger age, female gender, poorly differentiated grade and M1 stage was higher in SRCC than in NOS (P < .001). Multivariate analysis revealed that multiple metastatic sites (HR = 1.39, 95% CI: 1.14‐1.69, P = .001) was associated with increased mortality risk in metastatic SRCC. Median survival time was improved in metastatic SRCC receiving PG+C compared to PG/C alone (13 vs 7 months, P < .001). Notably, in subgroup analysis, 13 of 17 groups of metastatic SRCC patients with PG+C had prolonged overall survival compared to chemotherapy alone, especially for those with only one metastatic site (HR = 0.61, 95% CI: 0.51‐0.73, P < .001). Conclusions Our results suggested that there exists at least a selective group of stage IV gastric SRCC patients, who could benefit from palliative gastrectomy followed by chemotherapy compared to chemotherapy alone. Further prospective trials are needed to support our conclusion.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In the present study, we focused on group-3 patients (more advanced stage) for GALNT14 genotype and clinicopathological factors analysis. In clinicopathological factors analysis, under Cox proportional hazard multivariate models, patients with large tumor size, lymph node metastasis, distant metastasis and perineural invasion had poorer OS, which was in consistent with previously studies 22 , 28 , 29 . Additionally, we discovered that GALNT14-rs9679162”TT” genotype was also associated with poorer OS in group-3 patients.…”

Section: Discussionsupporting

confidence: 89%

“…The prevalence of gastric SRCC is 16.8-35.5 % among gastric cancer patients 19 - 21 and the incidence is increasing in recent decade 2 . Although it has been established that gastric cancer with pathological characteristics of signet ring cells harbors a significantly poorer outcome when compared with other types of gastric cancer 4 , 22 , 23 , the prognostic factors within gastric SRCCs themselves remain poorly defined. In the present study, it was found that a large proportion of gastric SRCC patients were diagnosed in early stages, with 39.48% in stage I and 14.70% in stage IIA ( Supplementary Table 1 ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype

et al. 2018

View full text Add to dashboard Cite

Background: Gastric signet ring cell carcinoma (SRCC) is a histologic variant characterized by abundant intracytoplasmic mucin. Although it has been recognized that gastric adenocarcinoma harboring this feature has poorer prognosis, prognostic stratification within gastric SRCCs themselves has not been clearly defined. N-acetylgalactosaminyltransferase14 (GALNT14) genotype has been associated to poorer treatment outcome in mucinous type colorectal cancer. Here we incorporated clinicopathological factors and GALNT14 genotype to stratify prognosis of advanced gastric SRCC.Methods: Totally 347 gastric SRCC patients were retrospectively enrolled for GALNT14 genotyping. Clinicopathological factors were included for prognosis stratification.Results: Of the 347 patients, 341 underwent radical-intent gastrectomy and 6 received palliative gastrectomy. Kaplan-Meier analysis for overall survival indicated that Tumor-Node-Metastasis staging could only stratify the patients into three prognosis-distinguishable groups: group-1 (stage IA); group-2 (stage IB/IIA) and group-3 (the remaining Tumor-Node-Metastasis stages combined). Multivariate Cox-proportional hazard models for group-3 patients revealed GALNT14 “TT” genotype (P = 0.0482). Tumor size (P = 0.0009), node status (P <0.0001), metastasis status (P = 0.0096), and perineural invasion (P = 0.037) independently associated with unfavorable OS. Exploratory subgroup analysis showed that GALNT14”TT” genotype was associated with unfavorable OS in SRCCs with more aggressive phenotypes: node status >0 (P = 0.0013), lymphatic invasion (P = 0.021), vascular invasion (P = 0.0076) and perineural invasion (P = 0.0161). Accordingly, a scoring system was established capable of stratifying advanced gastric SRCC patients into three distinguishable prognostic subgroups.Conclusions: Gastric SRCC could be stratified into different prognostic subgroups by combining clinicopathological factors and GALNT14 genotype.

show abstract

“…Regarding early SRCC, most studies have reported that this tumor type has less risk of lymph node metastasis and favorable prognosis compared with other types, 4 on the contrary other studies reported that SRCC had an unfavorable risk of lymph node metastasis, and thus a worse prognosis after surgical resection, compared to other GC types. 5,6 Moreover in advanced GC, SRCC was reported as an independent predictor of poor prognosis in multivariate analysis in some studies, 6,7 while it was not significant in other studies also performed by multivariate analysis after adjustment for the stage since the presence of SRCC are more frequently found at an advanced stage in GC than in other GC types. 8,9,10,11,12 While the incidence of GC has decreased worldwide in recent decades, the incidence of SRCC is constantly increasing in Asia, United States and Europe, accounting for 8% to 30% of GC cases in recent studies.…”

Section: Introductionmentioning

confidence: 96%

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach

Caggiari

Miolo

Canzonieri

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Germline mutations in CDH1, the gene coding for the E-cadherin adhesion protein, are known to cause hereditary diffuse gastric cancer. We identified a new truncating germline mutation (p.Asp538Thrfs*19) in exon 11 of the CDH1 gene in a 41-year-old male with a diffuse gastric cancer. Although he had no parental history of gastric cancer, the co-segregation study in the family detected the same mutation in his healthy 31-year-old brother. The mutation affects one of the extracellular repeat (CAD repeats) domains which is essential for the homophilic binding specificity that directs “E-cadherin” to bind with itself each others. In this case, immunohistochemical analysis showed no expression of E-cadherin in the tumor sample and was a useful prescreening tool to genetic testing. This finding was associated with a poor response to trastuzumab-based treatment.

show abstract

Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Cited by 14 publications

References 32 publications

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study

Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach

Contact Info

Product

Resources

About